Meta-Analysis:
Bevacizumab combined with chemotherapy for glioblastoma: a metaanalysis of randomized controlled trials
PDF | Full Text | How to cite
Shou-Bo Yang1, Kai-Di Gao2, Tao Jiang3, Shu-Jun Cheng1 and Wen-Bin Li1
1Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
2Beijing Rehabilitation Hospital of Capital Medical University, Beijing, China
3Department of Neurosurgery, Tiantan Hospital, Capital Medical University, Beijing, China
Correspondence to:
Wen-Bin Li, email: liwenbin@ccmu.edu.cn
Keywords: bevacizumab, chemotherapy, glioblastoma, meta-analysis, prognosis
Received: October 24, 2016 Accepted: March 22, 2017 Published: April 07, 2017
ABSTRACT
Bevacizumab, as antibodies, were applied to inhibit tumor angiogenesis by preventing activation of vascular endothelial growth factor receptor. We analyzed four clinical trials, including 607 patients, to investigate the efficacy and safety of bevacizumab when combined with chemotherapy for the treatment of glioblastomas. Results demonstrated that bevacizumab when combined with chemotherapy improved progression-free survival (HR = 0.66; 95% CI 0.56–0.78; p < 0.00001) compared with bevacizumab or chemotherapy alone. Furthermore, overall survival showed insignificant difference between two arms (HR 0.99; 95% CI 0.8–1.21; p = 0.92). However, we found that patients treated with bevacizumab-containing therapy reported increased objective response rate (OR 1.85, 95% CI 1.17–2.93; p = 0.009), but more treatment-related adverse events (OR 1.75; 95% CI 1.09–2.83; p = 0.02).